Full Press Release Details
MIAMI, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that members of its management team will participate in the following investor conferences:
Jefferies Global Healthcare Conference Date: November 16, 2026 Time: 1:00 p.m. GMT Format: Fireside Chat Presenter: Samuel J. Reich, Chief Executive Officer Location: London, UK
UBS Global Biopharma Conference Date: November 17, 2026 Time: 8:40 a.m. GMT Format: Fireside Chat Presenter: Samuel J. Reich, Chief Executive Officer Location: London, UK
9th Annual Evercore Healthcare Conference Date: December 1, 2026 Time: 2:35 p.m. EST Format: Fireside Chat Presenter: Samuel J. Reich, Chief Executive Officer Location: Coral Gables, FL
Citi Global Healthcare Conference Date: December 2, 2026 Format: One-on-one meetings Location: Miami, FL SAB BIO management will be available for one-on-one meetings during the conferences. Interested parties should contact their conference representative to arrange a meeting. To access a live or replay webcast of these events, please visit the Investors & Media section of the Company’s website at www.sab.bio.
About SAB BIO SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is being evaluated in two clinical trials: the registrational Phase 2b SAFEGUARD study for those newly diagnosed with Stage 3 T1D and the investigator-led Phase 3 PRISE-hATG study for people up to two years following a Stage 3 T1D diagnosis. For more information, visit www.sab.bio.